{"id":"cbdv-compound","safety":{"commonSideEffects":[{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"}]},"_chembl":{"chemblId":"CHEMBL6012633","moleculeType":null,"molecularWeight":"286.42"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CBDV is a phytocannabinoid structurally similar to CBD that interacts with cannabinoid receptors and other ion channels in the central nervous system. It is being investigated for its potential anticonvulsant and neuroprotective properties, particularly in conditions characterized by abnormal neuronal activity. The exact molecular mechanisms remain under investigation but may involve modulation of TRPV1, TRPA1, and other ion channels.","oneSentence":"CBDV (cannabidivarin) is a non-intoxicating cannabinoid that modulates endocannabinoid signaling and may reduce neuronal hyperexcitability.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:49:47.798Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (phase 2 investigation)"},{"name":"Autism spectrum disorder (exploratory)"}]},"trialDetails":[{"nctId":"NCT03848481","phase":"PHASE2","title":"CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2020-11-23","conditions":"Prader-Willi Syndrome","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CBDV Compound","genericName":"CBDV Compound","companyName":"Montefiore Medical Center","companyId":"montefiore-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CBDV (cannabidivarin) is a non-intoxicating cannabinoid that modulates endocannabinoid signaling and may reduce neuronal hyperexcitability. Used for Epilepsy (phase 2 investigation), Autism spectrum disorder (exploratory).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}